Cochrane Review: Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents

Zusammenfassung

# Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents. ## BACKGROUND Multiple myeloma is a malignant plasma cell disorder characterised by clonal plasma cells that cause end-organ damage such as renal failure, lytic bone lesions, hypercalcaemia and/or anaemia. People with multiple myeloma are treated with immunomodulatory agents including lenalidomide, pomalidomide, and thalidomide. Multiple myeloma is associated with an increased risk of thro

Kerninformationen

ceiving immunomodulatory agents who otherwise have no standard therapeutic or prophylactic indication for anticoagulation. (2) To maintain this review as a living systematic review by continually running the searches and incorporating newly identified studies. ## SEARCH METHODS We conducted a comp...

e new evidence rapidly after it is identified. ## SELECTION CRITERIA Randomised controlled trials (RCTs) assessing the benefits and harms of oral anticoagulants such as vitamin K antagonist (VKA) and direct oral anticoagulants (DOAC), anti-platelet agents such as aspirin (ASA), and parenteral anti...

isk ratio (RR) with its 95% confidence interval (CI) and the risk difference (RD) with its 95% CI. We then assessed the certainty of evidence at the outcome level following the GRADE approach (GRADE Handbook). ## MAIN RESULTS We identified 1015 identified citations and included 11 articles reporti...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen